Banerjee et al. synthesized 14 new PSMA-targeted, 177Lu-labeled radioligands (177Lu-L1–177Lu-L14) [5] and investigated their pharmacokinetics, capacity to kill cells in vitro, and tumor control in vivo. Here, FOLH1 is linked to neoplasm.